Transparency Market Research Report Added “Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs)” to its database.
Diabetes Devices and Drugs Market: Discription
Diabetes is a chronic metabolic disease wherein the body is either not able to produce insulin (type-1) or is not able to utilize the generated insulin (type-2). This elevated sugar level leads to various symptoms such as increased thirst, weight loss, high appetite, frequent and sweet smelled urination. If untreated, diabetes causes various acute and chronic life-threatening complications. This report studies the current as well as future scenario of the diabetes diagnostic devices and drugs market globally.
The diabetes diagnostic devices and drugs market has been segmented based on devices and drugs available for the treatment the disease. Based on device type, the market is segmented into diabetes diagnostic devices and insulin delivery devices. Diabetes diagnostic devices include analog blood meter, test strips, lancets and lancing devices, continuous glucose monitoring devices and others. The insulin delivery devices segment include insulin syringes, insulin pens, insulin pumps and insulin injectors.
Based on drugs, the market is segmented into insulin derivatives, oral anti-diabetes drugs and non-insulin injectable anti-diabetes drugs. The insulin derivatives segment is further categorized as rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. The oral anti-diabetes drugs segment includes various drugs classes such as sulphonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors, GPP-4 inhibitors and SGLT-2 inhibitors. The non-insulin injectable anti-diabetes drugs segment is segmented into GLP-1 analogs and Pramlintide. The market for these devices and drugs has been extensively analyzed based on demand for branded and generic products in each class of drugs and devices. Rising prevalence of diabetic population across various regions of the world, pipeline products from each class, rising preference of patients and healthcare professionals toward technologically advanced monitoring and insulin delivery devices is driving the growth of the diabetes diagnostic devices and drugs market.
Browse Market Research Report:
Diabetes Devices and Drugs Market: Snapshot
Diabetes is a group of metabolic disorders in which pancreas is not able to produce enough insulin (sugar metabolizing hormone) (type-1) or the body develops a resistance to produce insulin and is not able to utilize the produced insulin (type-2). This condition triggers various malignancies and diseases. Diabetes market is a consolidated market and the demand for various advanced devices and medicines is increasing steadily, owing to exponential growth in the prevalence of diabetes across the globe. This report is focused towards identifying the current scenario as well as the future market potential for diabetes drugs and devices globally.
The global diabetes devices and drugs market is segmented into two segments, namely; diabetes devices and diabetes drugs class. Diabetes devices segment is divided into diabetes diagnostic and monitoring devices and insulin delivery devices. Diabetes diagnostic and monitoring devices class is further split into analog glucose meters, test strips, lancets and lancing devices, CGM devices and others. Insulin delivery devices class is divided into insulin pens, insulin syringes, insulin pumps and insulin injectors. The second segment of the market, that is, drugs class is fragmented into insulin derivatives, oral anti-diabetes drugs (OADs) and non insulin injectable anti-diabetes drugs. Insulin derivatives are categorized on the basis of their time of action, such as, rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Oral anti-diabetes drugs are divided into sulphonylureas, biguanides, meglitinides, alpha glucosidase inhibitors, thiazolidinediones, DPP-IV inhibitors, and SGLT2 inhibitors. GLP-1 agonists represent the injectable anti-diabetes drugs class. The report also provides in-depth analysis of pipeline diabetes drugs.
Fill the form for an exclusive sample of this report: